Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KOSDAQ - Delayed Quote KRW

Synergy Innovation Co., Ltd. (048870.KQ)

Compare
3,175.00
-175.00
(-5.22%)
At close: April 18 at 3:30:15 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
90,605,209.44
90,605,209.44
83,214,793.56
86,539,071.42
80,964,297.30
Cost of Revenue
52,501,372.02
52,501,372.02
51,611,643.32
46,997,981.08
48,816,616.11
Gross Profit
38,103,837.42
38,103,837.42
31,603,150.24
39,541,090.34
32,147,681.19
Operating Expense
21,994,291
21,994,291
16,618,554
16,613,893
18,729,722
Operating Income
16,109,546.42
16,109,546.42
14,984,596.24
22,927,197.34
13,417,959.19
Net Non Operating Interest Income Expense
-926,771.30
-926,771.30
444,783.79
-2,120,757.68
-1,936,541.21
Pretax Income
21,797,105.51
21,797,105.51
26,710,672.39
14,674,003.05
11,899,934.37
Tax Provision
3,653,045.58
3,653,045.58
19,057,926.41
-10,716,768.59
2,231,567.98
Net Income Common Stockholders
10,370,684.40
10,370,684.40
2,304,761.75
16,127,599.56
5,719,033.40
Basic EPS
125.00
--
28.00
199.00
75.00
Diluted EPS
125.00
--
28.00
199.00
75.00
Basic Average Shares
82,965.48
--
82,312.92
81,043.21
76,409.43
Diluted Average Shares
82,965.48
--
82,312.92
81,043.21
76,409.43
Total Operating Income as Reported
16,109,545.84
16,109,545.84
14,984,595.60
22,927,197.27
13,417,959.57
Rent Expense Supplemental
85,314
85,314
89,816
92,333
82,929
Total Expenses
74,495,663.02
74,495,663.02
68,230,197.32
63,611,874.08
67,546,338.11
Net Income from Continuing & Discontinued Operation
10,370,684.40
10,370,684.40
2,304,761.75
16,127,599.56
5,719,033.40
Normalized Income
14,403,525.78
14,403,525.78
7,704,861.87
23,201,055.78
5,847,301.64
Interest Income
3,602,235
3,602,235
2,079,997
661,729
178,754
Interest Expense
4,618,600
4,618,600
2,023,203
2,761,671
2,115,295
Net Interest Income
-926,771.30
-926,771.30
444,783.79
-2,120,757.68
-1,936,541.21
EBIT
26,415,705.51
26,415,705.51
28,733,875.39
17,435,674.05
14,015,229.37
EBITDA
30,574,665.51
30,574,665.51
33,199,444.39
22,569,090.05
19,594,862.37
Reconciled Cost of Revenue
52,501,372.02
52,501,372.02
51,611,643.32
46,997,981.08
48,816,616.11
Reconciled Depreciation
4,158,960
4,158,960
4,465,569
5,133,416
5,579,633
Net Income from Continuing Operation Net Minority Interest
10,370,684.40
10,370,684.40
2,411,261.99
18,702,724.40
5,719,033.40
Total Unusual Items Excluding Goodwill
-4,844,796
-4,844,796
-6,965,263
-6,204,595
-157,874
Total Unusual Items
-4,844,796
-4,844,796
-6,965,263
-6,204,595
-157,874
Normalized EBITDA
35,419,461.51
35,419,461.51
40,164,707.39
28,773,685.05
19,752,736.37
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-811,954.62
-811,954.62
-1,671,663.12
-1,706,263.63
-29,605.76
12/31/2021 - 8/13/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

M1RN34.SA Moderna, Inc.
7.16
-5.79%
 
2181.HK Mabpharm Limited
0.495
0.00%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
285.400
-1.25%
 
TSBX Turnstone Biologics Corp.
0.3300
-3.79%
 
288330.KQ Bridge Biotherapeutics, Inc.
2,160.00
-29.87%
 
IMUC EOM Pharmaceuticals Holdings, Inc.
0.1390
0.00%
 
SNPX Synaptogenix, Inc.
2.1150
-2.98%
 
APRE Aprea Therapeutics, Inc.
1.5004
-1.29%
 
PMCB PharmaCyte Biotech, Inc.
1.1900
+5.31%
 
GTBP GT Biopharma, Inc.
2.2700
+0.89%